Background: 24-dehydrocholesterol reductase (Dhcr24) catalyzes the last step of
| INTRODUCTION
Cholesterol is an indispensable lipid involved in numerous processes that are required for the normal development and maintenance of tissues. 1 It is involved in signal transduction as a component of caveolae and lipid rafts and functions as a covalent modifier of the hedgehog family of morphogenes. Wechsler et al reported that DHCR24 À/À mice were viable up to adulthood and displayed no gross abnormalities, and it was found that cholesterol was not obligatory for viability. 4 In contrast,
Mirza et al indicated that DHCR24
À/À mice died within the early postnatal days and that Dhcr24 expression was essential for normal development. 5 Mutations in the Dhcr24 gene result in an autosomal recessive disease called desmosterolosis, which is indicated by developmental and growth retardation. 6 The reduced expression of the Dhcr24 gene is associated with increased apoptosis in adrenocortical cells as the result of caspase-3 inhibition, which is a mediator of the response to oxidative and oncogenic stress and a reactive oxygen species scavenger. 7 Furthermore, a reduced expression of Dhcr24 is also found in the temporal cortex of Alzheimer's disease patients and is associated with severe anomalies in development in which Dhcr24 is suggested to be involved in the antiapoptotic function in the brain, [8] [9] [10] and it may be a mediator of the protective effects of estrogen in neuronal cells. 11 Furthermore, Dhcr24, as a key mediator of Ras-induced senescence following oncogenic and oxidative stress, binds the p53 amino terminus and displaces the E3 ubiquitin ligase Mdm2 from p53, thus resulting in the accumulation of p53. 12 The administration of triparanol, an inhibitor of Dhcr24, into pregnant rats or mice caused the accumulation of desmosterol, zymosterol and hypocholesterolemia, and was highly teratogenic. 13 Therefore, Dhcr24 is a multifunctional protein possessing both cholesterol synthesizing and anti-apoptotic activities.
Dilated cardiomyopathy (DCM) is a primary heart muscle disease characterized by the dilation of the heart chambers with evidence of impaired systolic function. Idiopathic dilated cardiomyopathy (IDC) has a prevalence of 1:2500 and is a common cause of heart failure, especially in the young, and the disease is believed to be caused by mutations in up to 50% of the cases. Despite recent advances in pharmacological and surgical therapies, the disability and morbidity due to DCM is still high. [14] [15] [16] The missense mutation R141W, in the strong tropomyosin-binding region of cardiac troponin T (cTnT), causes familial dilated cardiomyopathy (FDC). 17, 18 We reported that cTnT R141W transgenic mice manifested progressive chamber dilation and contractile dysfunction and had a pathological phenotype similar to that of human DCM. 19 Dhcr24 mRNA expression was down-regulated in the cTnT R141W transgenic mice at 3 months of age, at which time the mice developed a typical cardiomyopathy phenotype.
Therefore, we generated cardiac-specific overexpression of Dhcr24 transgenic mice to study whether compensated expression of Dhcr24 in the heart tissues could ameliorate the DCM phenotypes in the mice and uncover its possible mechanism.
2 | METHODS
| Animals
The a-MHC-cTnT R141W transgenic mice were generated in our laboratory and exhibited DCM phenotype characteristics consistent with previously reports. 19 Mouse Dhcr24 cDNA (Genbank accession no. 
| Cell culture
The H9c2 cells line were grown in high glucose DMEM supplemented with 10% defined fetal bovine serum (HyClone), 100 U/mL penicillin and 100 g/mL streptomycin (HyClone) in a humidified 5% CO 2 incubator at 37°C. The expression construct was individually generated by cloning the full-length Dhcr24 cDNA fragment into the pcDNA3.1(+) vector (Invitrogen). The expression construct for the Dhcr24 siRNA was a commercial product (OriGene), which corresponded to the sequence of ATGTTCGATGGCTCCTTGTACCA-CAAGCT in the 3ʹUTR of the Dhcr24 cDNA of mouse and rat. H9c2 cells were transfected with the constructs using Lipofectamine 2000 (Invitrogen). Stable cell lines were established by subsequent selection using 800 lg/mL G418 (Amresco 
| Survival analysis
The cumulative percent mortality was calculated every month. Upon the death of each mouse, the body was autopsied by a pathologist, and morphological and pathological changes in the heart were recorded. Kaplan-Meier curves for survival analysis were compared using the log-rank test (SPSS. 16.0 software). 
| Histological analysis

| Protein extraction and immunoblotting
Total protein lysates from the mouse heart tissue or the cultured cells were prepared by homogenizing with lysis buffer ( 
| TUNEL assay
The in situ terminal dUTP nick end-labeling (TUNEL) assay was per- 
| Statistical analysis
The data were analysed with one-way ANOVA for multiple groups followed by Tukey's post hoc analysis. The data are expressed as means AE SEMs from the individual experiments. Differences were considered significant at P < .05.
3 | RESULTS
| Dhcr24 expression down-regulated in the heart tissue during aging and the development of DCM
The expression of Dhcr24 in the heart tissue of wild type (WT) mice at different ages was detected by Western blot with an anti-Dhcr24
antibody. The results indicated that Dhcr24 expression in the heart down-regulated during aging, with its expression level reduced by 42% until 6 months of age ( Figure 1A ,B). The expression of Dhcr24 in the heart tissue of the cTnT R141W mice at 3 months of age downregulated by 52% compared with that of the non-transgenic (NTG)
littermates ( Figure 1C ,D, n = 3 mice per group, P < .01 versus NTG littermates). The decreased expression was also observed by immunohistochemical staining of the heart sections of the cTnT R141W mice during the development a typical cardiomyopathy phenotype ( Figure 1E ). The cholesterol in the cTnT R141W hearts decreased by 42% compared to that of the NTG mice, which was a result of the down-regulation of Dhcr24 ( Figure 1F , n = 6 mice group, P < .01 versus NTG littermates).
| The generation of heart-specific Dhcr24 transgenic mice
To produce the transgenic construct, the mouse Dhcr24 cDNA was inserted downstream of the a-myosin heavy chain (MHC) cardiacspecific promoter, and the transgenic mice were generated by the microinjection method ( Figure 2A ). The transgenic founders were selected by Western blot. The Dhcr24 levels in the heart tissue of the founders were increased by 24% compared with that of the NTG mice at 1 month of age (Figure 2B ,C; n = 3 mice per group, P < .01 versus NTG littermates). The high level of Dhcr24 in the transgenic mice was also observed by immunohistochemical staining ( Figure 2D ). In addition to the increased expression of Dhcr24, cholesterol was also increased by 29% in the Dhcr24 hearts compared to those of the NTG mice ( Figure 2E , n = 6 mice per group, P < .01 versus NTG littermates).
| The transgenic overexpression of Dhcr24
improves cardiac geometry and dysfunction and decreases mortality in cTnT R141W mice
The ventricular size and function of the NTG, Dhcr24, cTnT R141W and the Dhcr24 and cTnT R141W double transgenic mice (referred to as DTG) mice were assessed using echocardiography at 1, 3, 5, and 7 months of age. The representative M-mode echocardiographic images at 5 months of age were shown in Figure 3A . The left ventricular (LV) posterior wall at end-systole (LVPWS) of the DTG mice was cumulatively increased by 11% at 3 months of age and reached up to 24% at 7 months of age compared with that of the cTnT R141W transgenic mice, in which the LVPWS decreased slowly during the development of DCM ( Figure 3B ). The LV fractional shortening (LVFS) of the DTG mice was significantly increased by 19% to 22% compared with that of the cTnT R141W mice ( Figure 3C ) from 1 to 7 months of age. The DCM phenotypes were significantly improved when the decreased expression of Dhcr24 was rescued in the DTG mice. The typical M-mode echocardiography parameters at 5 months of age are summarized in Table 1 . The survival rate was 65% in the cTnT R141W mice, while the survival rate was increased to 98% in the DTG mice until 7 months of age ( Figure 3D , n = 16 mice per group). Figure 5C -E, n = 3 mice per group, P < .05 or P < .01 versus cTnT R141W group). Activated caspase-9 and -3 increased by 322% and 261%, respectively, in the heart tissues of the cTnT R141W transgenic mice compared with that of the NTG mice (Figures 5F,G; n = 3 mice per group, P < .01 versus NTG littermates), and the activation of caspase-9 and -3 reduced by 71%
and 73%, respectively, due to the overexpression of Dhcr24 in the DTG mice (Figures 5E,F; n = 3 mice per group, P < .01 versus cTnT R141W group). respectively) were established and used for analysis of the PI3K pathway and apoptosis. The Dhcr24-ov cells showed a 72% increased expression of Dhcr24, which resulted in increased PI3K, AKT phosphorylation and HKII by 127%, 222% and 150%, respectively, compared with that of the parental H9c2 cells (Figure 7A ,B; n = 3 independent experiments, P < .01 versus control group). In contrast, the Dhcr24-kd cells showed a 58% decreased expression of Dhcr24, which decreased the expression of PI3K, AKT phosphorylation and HKII by 21%, 41%
and 60%, respectively, compared with that of the parental H9c2 cells (Figure 7A ,B; n = 3 independent experiments, P < .05 or P < .01 versus control group). The translocation of Bax and the release of cytochrome c were reduced by 59% and 48%, respectively, in the Dhcr24- Cholesterol is an essential biological molecule in animals that is involved in signal transduction as a component of caveolae and lipid rafts and functions as a covalent modifier of the hedgehog family of morphogenes. 2, 3 Dhcr24 catalyzes the last step of cholesterol biosynthesis to convert desmosterol to cholesterol, and the expression of Dhcr24 has been detected in many different organs, including the brain, adrenal thyroid gland, ovary, testis and prostate. 8, 22 We found that Dhcr24 expressed in heart tissue of mouse, and its expression reduced by 42% at 6 months of age compared with 1 month of age ( Figure 1A ), which suggested that Dhcr24 expression down-regulated during aging (Dhcr24 expression was also observed in human heart tissues at different ages by immunohistological staining, Figure S1 ). Interestingly, the expression of Dhcr24 significantly down-regulated in the DCM heart tissues from both of the cTnT R141W ( Figure 1C,D) and LMNA E82K transgenic mice ( Figure S2 ), which resulted in the decrease of cholesterol ( Figure 1F ). Dhcr24 is involved in anti-apoptotic function in the brain, and its reduced expression in the temporal cortex is involved in the pathological development of Alzheimer's disease. 8, 9, 11 Our results suggested that reduced Dhcr24 expression was also associated with DCM in the
The measurement of signalling proteins of the PI3K and the mitochondrial pathways of apoptosis. The heart tissues were sampled from the NTG, Dhcr24, cTnT R141W and DTG mice at 5 mo of age. (A), The levels of Dhcr24, PI3K, phosphorylated AKT and HKII were detected by Western blot in the heart tissues. (B), Quantitatively analyzed using GAPDH for normalization. (C), The fraction of Bax and cytochrome c in the cytoplasm and the mitochondria was detected in the heart tissues by Western blot. (D), (E), Quantitatively analysis using COX4 and GAPDH for normalization, respectively. (F), The activation of caspase-9 and -3 was measured by Western blot. (G), Quantitatively analyzed using GAPDH for normalization mouse models. We generated a heart tissue-specific transgenic mouse with increased Dhcr24 expression and cholesterol ( Figure 2 ).
The transgenic overexpression of Dhcr24 significantly improved cardiac geometry and dysfunction and decreased the mortality of the cTnT R141W transgenic mice ( Figure 3 and Table 1 ). Furthermore, the transgenic overexpression of Dhcr24 ameliorated the obvious cardiac pathological phenotype in the cTnT R141W transgenic mice (Figure 4 ).
Cardiomyocyte cell death is a major factor that contributes to pathological heart disease. All three types of cell death (necrosis, apoptosis, and autophagy) are present in heart failure. 23, 24 Based on clinical and animal studies, myocyte apoptosis plays an important role in the pathogenesis of cardiovascular diseases, such as ischemic heart disease, atherosclerosis, cardiomyopathy, and heart failure. [25] [26] [27] [28] [29] [30] Both of the DCM mouse models, the cTnT R141W and the LMNA E82K transgenic mice, were generated in our laboratory and show apoptosis in the heart. 31, 32 PI3K-dependent signaling is an ubiquitous pathway involved in cell growth, proliferation, survival, migration, metabolism and several other biological responses, including cardiomyocyte growth, survival, and contractility, as well as cardiovascular inflammation. [33] [34] [35] Akt is one of the primary downstream effectors in the PI3K pathway, which is phosphorylated at Thr308 and Ser473 to generate its active form and controls a variety of responses in the heart, such as inhibition of apoptosis, regulation of cell proliferation, metabolism and hypertrophy. [36] [37] [38] HKII is also one of the downstream effectors in the PI3K pathway. 39, 40 HKII is phosphorylated by Akt and mediates protection against Ca 2+ overload in isolated heart mitochondria and against H 2 O 2 -induced injury in neonatal rat ventricular myocytes 
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